hyperlipidemias

Lorlatinib and New-Onset Diabetes Practical Monitoring for Oncologists

Patients on lorlatinib require vigilant monitoring for hyperglycemia and ketoacidosis, regardless of pre-existing diabetes risk factors. Proactive screening and early intervention are crucial to mitigate potential severe complications and ensure patient saf...

Lorlatinib and the Enigma of Autoantibody-Negative Diabetes

Patients on lorlatinib may develop diabetes with unusual characteristics, including the absence of typical autoantibodies. This presents a diagnostic challenge, requiring clinicians to consider drug-induced etiologies even when initial immunological markers...